NURO Stock Overview
A commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NeuroMetrix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.79 |
| 52 Week High | US$9.20 |
| 52 Week Low | US$2.70 |
| Beta | 2.28 |
| 1 Month Change | -11.86% |
| 3 Month Change | 1.88% |
| 1 Year Change | -52.62% |
| 3 Year Change | -86.02% |
| 5 Year Change | -92.11% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
NeuroMetrix reports Q3 results
Oct 20NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years
Sep 23NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M
Jul 21We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely
May 11
Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation
Jan 19NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation
Sep 09We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely
Jul 21NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans
Jan 27
Shareholder Returns
| NURO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -4.3% | -0.6% | -0.6% |
| 1Y | -52.6% | 2.1% | 22.4% |
Return vs Industry: NURO underperformed the US Medical Equipment industry which returned 1.9% over the past year.
Return vs Market: NURO underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| NURO volatility | |
|---|---|
| NURO Average Weekly Movement | 8.5% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NURO has not had significant price volatility in the past 3 months.
Volatility Over Time: NURO's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 26 | Shai Gozani | www.neurometrix.com |
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons.
NeuroMetrix, Inc. Fundamentals Summary
| NURO fundamental statistics | |
|---|---|
| Market cap | US$7.61m |
| Earnings (TTM) | -US$7.98m |
| Revenue (TTM) | US$5.27m |
1.4x
P/S Ratio-0.9x
P/E RatioIs NURO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NURO income statement (TTM) | |
|---|---|
| Revenue | US$5.27m |
| Cost of Revenue | US$2.00m |
| Gross Profit | US$3.27m |
| Other Expenses | US$11.25m |
| Earnings | -US$7.98m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.02 |
| Gross Margin | 61.97% |
| Net Profit Margin | -151.51% |
| Debt/Equity Ratio | 0% |
How did NURO perform over the long term?
See historical performance and comparison